.
MergerLinks Header Logo

New Deal


Announced

IMCD to acquire Whawon Pharm.

Financials

Edit Data
Transaction Value-
Consideration TypeCash
Capital Owned-
Capital Bid For57%
EV/Sales-
EV/EBITDA-
Share Price Premium-
One Off Charge-

Tags

Edit

South Korea

pharmaceutical ingredient distributor

Friendly

Single Bidder

Pending

Private

Pharmaceuticals

Acquisition

Synopsis

Edit

IMCD, a leading distributor of speciality chemicals and food ingredients, agreed to acquire 57% of the outstanding shares of South Korean based pharmaceutical ingredient distributor Whawon Pharm. In 2018, the company generated a revenue of KRW 57bn ($49m) with 54 employees. "MCD is an ideal partner for Whawon as they share a similar business culture and have a highly dedicated global pharmaceutical presence. We look forward to utilising their technical capability to further develop growth for our customers and suppliers," Young-Hee Won, Whawon CEO.

Search a database of more than 250,000 verified dealmakers

Receive automated updates on global transactions

Follow the activity, relationships and transactions of top dealmakers

No credit card required

© COPYRIGHT 2024 MERGERLINKS LIMITED.

ALL RIGHTS RESERVED.

15 BONHILL STREET, LONDON, EC2A 4DN, UNITED KINGDOM.

CONTACT US